New antibiotic takes on superbug in major hospital study

NCT ID NCT07226557

Ongoing Disease control Sponsor: National Institutes of Health Clinical Center (CC) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether the antibiotic cefiderocol can lower death rates in hospitalized adults with a tough, drug-resistant Acinetobacter infection. Researchers will compare patients who got cefiderocol to those who received the best available treatment. The goal is to see which approach works better over 28 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cefiderocol
What this could lead to: If cefiderocol works better, it could become a go-to treatment for tough hospital infections that resist other antibiotics.
What could go wrong: This is an observational analysis, not a controlled trial, so results may be less reliable. The infection is rare and severe, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACINETOBACTER BAUMANNII INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acinetobacter infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACINETOBACTER BAUMANNII INFECTION ANTIMICROBIAL DRUG RESISTANCE CARBAPENEM RESISTANT BACTERIAL INFECTION

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.